Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Dextera Surgical target lowered to $3.50 at Wedbush — Liquidity concerns overshadow improving MicroCutter adoption (1.34)Wedbush lowers their DXTR tgt to $3.50 from $5. DXTR continues efforts to expand MicroCutter adoption and reported MicroCutter Product Sales results that reflect notable sequential improvement; however, the company will need to raise capital or sell the company over the next few months. Firm notes three key takeaways that bode positively for MicroCutter 5/80 adoption: 1) Mgmt anticipates 60+% qtr/qtr MicroCutter sales during the next 2 quarters; 2) DXTR is expanding is sales reps; 3) 38 reordering surgeons (10 US/28 EU) with a target of 75 by the end of CY2Q17; 4) Increasing awareness of the MicroCutter 5/80 through a distribution partnership with B. Braun in Spain as well as clinical presentations at the recent Society of Thoracic Surgeons annual meeting (Jan 2017); Outperform.</td> </tr></table>"